reason report
adro-nv sting collabor back draw board
bottom line yesterday report link novarti
nv cover discontinu evalu
intratumor sting agonist reset scope on-go
sting collabor focu discoveri effort system
sting deliveri follow discontinu remov revenu
cost associ combin spartalizumab
ipilimumab continu trial
pembrolizumab op squamou cell carcinoma head
neck scchn start anoth trial single-ag non-
muscl invas bladder cancer nmibc given reduct shots-
on-goal lower price target valu
potenti launch scchn though valu indic
believ nmibc great set sting-agon proof-of-
concept given posit fergen registration-en result
direct deliveri type interferon link also enthusiast
system deliveri sting given numer challeng
optim dose intratumor administr link
base clinic data date novarti discontinu on-go
studi evalu combin spartalizumab
ipilimumab spartalizumab object respons
rate orr evalu patient highli heterogen patient
popul link pay wall link said interest signal
combin seen tripl neg breast cancer tnbc patient
orr evalu patient intend report final
updat result trial ipilimumab combin trial
focus melanoma spartalizumab
relaps refractori melanoma disappoint orr
evalu patient especi consid posit result
agonist oncolyt virus set link
aduro continu evalu combin
pembrolizumab scchn enrol phase clinic trial
combin pembrolizumab first-lin treatment
recurr metastat scchn interim data combin
present though studi fund aduro
novarti partnership resum move registration-en
trial aduro manag told us phone call object
respons rate roughli doubl seen pembrolizumab
alon would meet bar move registration-en trial
model assum develop commerci mileston
novarti still possibl
year price history/av daili volume mil
compani inform svb leerink llc research
revenu ep quarterli figur may sum annual total due round
pleas refer page import disclosur price chart analyst certif
see glimmer hope novarti aduro continu collabor
develop systemic-deliv sting-agonist previous note sever dose
schedul question intratumor deliveri sting agonist link
continu believ underli biolog sting activ recogn
intricaci local deliveri take time solv think system dose
via tumor-select deliveri sting excit potenti reach metastat
site target deliveri specif cell type extend pharmacokinet profil
potenti less risk immun cell exhaust sever compani
system sting tlr agonist develop includ bolt biotherapeut privat
codiak bioscienc privat op chang trillium tril cover link
suffici cash runway end cash
cash equival
outperform rate pt base valu clinical- stage sting agonist
program sting rank top mechan medacorp io
kol panel complementari checkpoint inhibit posit impact four step
adapt immun cycl well nk cell remain posit sting agonist
depth biolog evid complementar checkpoint inhibit
multipl mechan prime adapt innat immun system though earli
also excit potenti valu sting inhibit auto-immun diseas
pursu collabor
project revenu deriv mont carlo simul rang outcom
part entir io industri pipelin valuat price target base
blend dcf analysi multipl simul revenu cga
collabor take account net cash hand overhead
sting scope restrict intratumor deliveri and/or limit abscop effect sting
therapeut window prove narrow effect optim patient failur
sting random trial reduc enthusiasm entir sting class
despit wide variat sting molecul select potenc differenti biolog sting
versu competit arriv ever-expand class sting molecul new
deliveri platform gsk sbph codiak other well relat
class agonist oncolyt virus
stock ticker symbol later impact companies/stock drug brand chemic name indicationtyp eventev trial detailsexpectedtimingspecif event date known specifi evid bar signal io-team view impact igh ow data presentationreport interim studi result othersphas data presentationreport complet dose esclat enrich nephropathi igan phase data presentationreport data igan sourc svb leerink llc equiti research compani file aduro inc
annual risk-adjust aaaaaaeeeeeeeein except per share sub-lin cga collaboration- non-product cogs- gross amort intang oper non op incom net common share aduro inc
annual current cash market secur account inventory- prepaid expens non-curr market secur properti equip lt total liabil total current account accru expens net- defer revenu short term debt- non-current senior secur note net- royalti liabilities- defer revenue less lt total stockhold prefer stock- common capit excess par accumul accumul aduro inc
annual net non-cash royalti revenu non-cash interest expens defer revenue- depreci stock base oper cash defer incom tax increas /decreas work capit financ incl fx proce stock issuanceoth oper cash floweffect fxnet increas decreas cash cash equivalentsrestrict cashcash balanc incl current market securitiesbegin end aduro inc
daina graybosch ph certifi view express report accur reflect view part
compens directli relat specif recommend view contain report
rate price target histori inc
leerink initi coverag outperform rate may
creat bluematrix
project revenu deriv mont carlo simul rang outcom part
entir io industri pipelin valuat price target base blend dcf analysi
multipl simul revenu cga collabor take account net cash hand
overhead
risk valuat
sting scope restrict intratumor deliveri and/or limit abscop effect sting therapeut window prove
narrow effect optim patient failur sting random trial
reduc enthusiasm entir sting class despit wide variat sting molecul select potenc
differenti biolog sting versu competit arriv ever-expand class sting molecul
new deliveri platform gsk sbph codiak other well relat class
agonist oncolyt virus
rate price target histori glaxosmithklin plc gsk ln
leerink initi coverag gsk ln market perform rate nov
creat bluematrix
rate price target histori merck co inc
leerink place market perform rate februari
creat bluematrix
price target base dcf use wacc account net cash project
revenu gener rang outcom keytruda mrk io asset deriv mont
carlo simul entir io industri pipelin develop path iter model growth
vaccin hiv franchis consensu estim vertic
risk valuat
increment scientif innov io may continu prove difficult initi burst
fail pursu most-promis add-on therapi bd competitor reli deeper intern pipelin
price reimburs relat risk
us legisl affect drug price propos price model risk commerci pharma
keytruda exposur medicar part could make particularli sensit
us health-system reform oncolog model remov practic incent prefer high-volum high-reb
option major leg keytruda competit moat
risk reimburs enhanc oversea re-negoti drug switch routin
practic low-cost local altern china could drive price one keytruda fastest grow market
rate price target histori inc
creat bluematrix
price target base blend revenu multipl analysi dcf analysi
assign valu probability-weight sale royalti probabl success ovarian
probabl success lung cancer use discount rate termin growth rate
risk valuat
pipelin program face clinic regulatori develop risk well commerci intellectu
properti risk also face execut risk financi risk may addit financ need
rate price target histori inc
creat bluematrix
estim per share valu share month base dcf analysi assum discount
rate termin growth rate account risk clinic regulatori drug develop probabl
success estim rang pku immuno-oncolog
valuat paramet reflect promis preclin data view off-set uncertain safety/efficaci profil
candid still earli stage develop
risk valuat
develop proprietari platform transloc metabol function variou organ gut
novel approach innov platform come high safeti efficaci risk although preclin
data seem convinc platform earli stage develop clinical/regulatori develop could
recept unanticip complic could impact stock neg
distribut ratings/invest bank servic ib
explan rate
outperform buy expect stock outperform benchmark next month
market perform hold/neutr expect stock perform line benchmark next
under-perform sell expect stock under-perform benchmark next month
degre out-performance under-perform requir warrant outperform under-perform
rate commensur risk profil compani
purpos definit relev benchmark issuer
market capit less billion issuer market
capit billion
